AMYOTROPHIC LATERAL SCLEROSIS

This study tested whether a drug called deferiprone, which removes extra iron from the brain, could slow the progression of ALS (Lou Gehrig's disease). The trial included 372 adults with early-stage ALS. Researchers measured changes in physical function and survival over 12 month…

This study tested a new drug called PrimeC in 69 people with ALS (Lou Gehrig's disease) to see if it is safe and can slow the disease. Participants took PrimeC or a placebo twice daily for 6 months, and everyone who finished could then receive PrimeC for another 12 months. The go…

This early-phase study tested whether a combination of two drugs, abatacept and interleukin-2, is safe for people with ALS. The goal was to increase the number and activity of regulatory T cells, which may help slow the disease. Five participants were enrolled, and the main focus…

This study tested a drug called ABBV-CLS-7262 in 310 people with ALS, a progressive nerve disease that weakens muscles. The goal was to see if the drug could slow down the disease and help people live longer or maintain function. While the treatment aims to control the disease, i…

This study tested whether a combination of curcumin and resveratrol (natural anti-inflammatory compounds) plus the drug G04CB02 can help people with ALS. 60 adults with ALS took either the treatment or a placebo for 2 months. Researchers measured muscle function, breathing, and i…

This study tested whether a low dose of interleukin-2 (IL-2), a protein that helps regulate the immune system, is safe and can increase regulatory T cells in people with amyotrophic lateral sclerosis (ALS). 36 adults with ALS received either IL-2 or a placebo for five days. The m…

This study looked at the long-term safety of a drug called Engensis in 8 people with ALS who had already received the drug in an earlier trial. Researchers monitored side effects over 6 months. The goal was to see if repeated injections are safe, not to test if the drug works.

This study tested the drug baricitinib, currently used for arthritis, in 17 people with Alzheimer's disease, ALS, or early memory problems. The goal was to see if the drug could reach the brain and reduce inflammation linked to these diseases. Participants took the drug for 24 we…

This study tested whether a daily ketone drink could slow the progression of ALS, a nerve disease that weakens muscles. 81 adults with ALS took either the drink or a placebo for 6 months. Researchers measured changes in a blood marker called neurofilament light chain and tracked …

This study tested a drug called DNL343 in 249 people with ALS, a disease that weakens muscles over time. The goal was to see if DNL343 could slow the disease and help people live longer. The trial compared DNL343 to a placebo over 24 weeks, measuring changes in physical function …

This study tested a low-dose immune treatment (IL-2) in 304 people newly diagnosed with ALS, a serious nerve disease. The goal was to see if boosting certain immune cells could slow the disease and help people live longer. Participants received either the drug or a placebo for 18…

This study tested the safety of an experimental drug called engensis in 18 people with amyotrophic lateral sclerosis (ALS), a disease that weakens muscles over time. Participants received either engensis or a placebo injection into their muscles. The main goal was to check for si…

This study tested a new drug called IFB-088 added to the standard ALS medication riluzole in 51 people with bulbar-onset ALS (a form that first affects speech and swallowing). The goal was to see if the combination is safe and shows signs of slowing the disease. Participants rece…

This study tested a drug called Lenzumestrocel in 123 people with ALS, a progressive nerve disease. The goal was to see if repeated doses could slow the disease and improve survival compared to a placebo. The trial was completed, and results are being analyzed.

This study tested a drug called TPN-101 in 42 people who have ALS (Lou Gehrig's disease) or frontotemporal dementia (FTD) caused by a specific genetic change in the C9orf72 gene. The main goal was to see if the drug is safe and tolerable when taken for up to 48 weeks. Researchers…

This study tested a custom-made drug designed for one person with ALS caused by a specific genetic change in the TARDBP gene. The drug aims to slow disease progression by targeting the genetic root of the condition. The participant's muscle strength, breathing, and thinking skill…

This study looked at whether tears and cells from the eye's surface can help diagnose ALS or predict how the disease will progress. Researchers compared samples from 55 people with ALS and healthy controls. The goal was to find chemical markers that could lead to a simple, non-in…

This study tested whether an online mindful community could improve quality of life for people with ALS and their caregivers. About 100 participants took part in a three-week e-learning program plus a social forum to practice mindfulness together. The goal was to reduce stress an…

This early-stage study tested whether a drug called VM202 is safe to inject into muscles of people with amyotrophic lateral sclerosis (ALS). 18 adults with early ALS received the injections and were monitored for 9 months. The main goal was to check for side effects, not to cure …

This study looked at 500 people with ALS (a nerve disease that weakens muscles) to find signs—called biomarkers—that could predict how fast the disease will progress and how long patients might live. Researchers collected medical images, blood samples, and electrical tests of ner…

This study followed 50 adults with a specific gene mutation (C9ORF72) that can cause either ALS or frontotemporal dementia. Researchers tracked changes in strength, thinking, memory, and behavior over three years using brain scans, spinal fluid tests, and other exams. The goal wa…

This study looked at how ALS affects the brain's ability to prepare and start walking, especially in people with balance problems. Researchers compared 59 participants (ALS patients with and without balance issues, plus healthy volunteers) using motion sensors and brain scans. Th…

This study aimed to find biological markers (biomarkers) in muscle, blood, and special cells that could help doctors diagnose amyotrophic lateral sclerosis (ALS) earlier and understand the disease better. Researchers studied samples from 37 adults with ALS. The goal was to identi…

This study compared 400 people with ALS (a nerve disease) and 400 healthy people to see if differences in vitamin D-related genes are linked to the disease. Researchers analyzed DNA samples for specific gene variations. The goal was to better understand the disease, not to test a…

This study looked at 44 people with ALS and healthy volunteers to see how gut bacteria byproducts (short-chain fatty acids) change over time and with diet. Researchers measured these substances in the blood at the start, after 6 months of disease progression, and after 6 months o…

This study looked at blood cells from people with Parkinson's disease, ALS, and healthy volunteers to understand how a drug called deferiprone affects cell stress and energy use. Researchers collected samples from 90 participants and tested the drug in the lab. The goal was to le…

This early study tested a simple technique called remote ischemic conditioning (RIC) in 21 people with spinal cord injury or ALS. RIC involves briefly restricting blood flow to a limb using a blood pressure cuff, which may trigger the body's natural repair systems. The goal was t…

This early-stage study tested a single dose of the experimental drug QRL-101 in 12 people with ALS. The main goal was to understand how the drug behaves in the body and to check for safety and side effects. Participants were randomly assigned to receive either QRL-101 or a placeb…

This study looked at 52 people with ALS and healthy volunteers to find out how the disease affects the sense of touch and movement, even when patients don't notice it. Using brain scans and electrical recordings, researchers aimed to link these hidden sensory problems with change…

This study looked at what unpleasant sensations or pain people with ALS experience during clinical trial procedures like tests or drug administration. Researchers interviewed 15 patients to understand their discomfort and how it affects their willingness to stay in trials. The go…

This early study tested whether a focused ultrasound technique could safely open the blood-brain barrier in the motor cortex of people with ALS. Four participants underwent the procedure to see if it was feasible and well-tolerated. The main goal was to check for side effects, no…

This study looked at how metabolism is altered in people with ALS, a disease that affects nerve cells and has no cure. Researchers collected skin and blood samples from 9 ALS patients to analyze their metabolic profiles. The goal was to better understand the disease, not to test …

This study aims to find new markers in MRI scans that could help doctors detect ALS earlier and track how it progresses over time. Researchers will use advanced 3T and 7T MRI machines to scan the brain, spinal cord, and muscles of 22 ALS patients at three different time points. T…